Liposarcoma

Subscribe to Selected New Research on Liposarcoma

460 relevant articles (12 outcomes, 42 trials/studies) found for this Disease

Description: A malignant tumor derived from primitive or embryonal lipoblastic cells. It may be composed of well-differentiated fat cells or may be dedifferentiated: myxoid (LIPOSARCOMA, MYXOID), round-celled, or pleomorphic, usually in association with a rich network of capillaries. Recurrences are common and dedifferentiated liposarcomas metastasize to the lungs or serosal surfaces. (From Dorland, 27th ed; Stedman, 25th ed)

Also Known As:

Dedifferentiated Liposarcoma; Dedifferentiated Liposarcomas; Liposarcomas; Liposarcomas, Dedifferentiated; Liposarcomas, Pleomorphic; Pleomorphic Liposarcoma; Pleomorphic Liposarcomas; Liposarcoma, Dedifferentiated; Liposarcoma, Pleomorphic

Relationship Network

Disease Context: Research Results

Neoplasms: 387640

Neoplasms by Histologic Type: 1

Connective and Soft Tissue Neoplasms

Sarcoma: 10281

Liposarcoma: 460

Myxoid Liposarcoma: 62

Adipose Tissue Neoplasms: 1

Liposarcoma: 460

Myxoid Liposarcoma: 62

Related Diseases

1.	Lipoma (Lipomata)
2.	Neoplasms (Cancer)
3.	Sarcoma (Soft Tissue Sarcoma)
4.	Fibrosarcoma
5.	Synovial Sarcoma (Synovioma)

Experts

1.	Oda, Yoshinao: 3 articles (01/2007 - 09/2002)
2.	Iwamoto, Yukihide: 3 articles (01/2007 - 09/2002)
3.	Yen, Gow-Chin: 2 articles (10/2008 - 06/2006)
4.	Hsu, Chin-Lin: 2 articles (10/2008 - 06/2006)
5.	Sánchez-Martín, Manuel: 2 articles (01/2008 - 10/2007)
6.	Sánchez-García, Isidro: 2 articles (01/2008 - 10/2007)
7.	Sakamoto, Akio: 2 articles (01/2007 - 09/2002)
8.	Tanaka, Kazuhiro: 2 articles (01/2007 - 12/2005)
9.	Matsuda, Shuichi: 2 articles (01/2007 - 12/2005)
10.	Coindre, Jean-Michel: 2 articles (04/2006 - 09/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Liposarcoma:

1.	PPAR gammaIBA 05/01/2008 - "This is the first study demonstrating the utility of PPAR-gamma immunohistochemistry in the diagnosis of dedifferentiated liposarcoma in tissue sections" 10/01/2007 - "Taken together, this study provides genetic evidence that the presence of FUS-DDIT3 in an aP2-positive cell is not enough to cause liposarcoma development and establishes that PPARgamma inactivation is required for liposarcoma development." 05/01/2008 - "Although not completely specific, the presence of PPAR-gamma staining, in combination with histologic findings and other markers, can aid in the diagnosis of dedifferentiated liposarcoma, particularly on small biopsies that may not sample the well-differentiated component." 10/01/2007 - "Fat-specific FUS-DDIT3-transgenic mice establish PPARgamma inactivation is required to liposarcoma development." 05/11/2000 - "We have demonstrated that liposarcomas in the FUS-CHOP transgenic mice express high levels of the adipocyte regulatory protein PPARgamma, whereas it is not expressed in embryonic fibroblasts from these animals following induction to differentiation toward the adipocyte lineage, indicating that the in vitro system does not really reflect the in vivo situation and the developmental defect is downstream of PPARgamma expression" Order ALL the reference details at left...
2.	troglitazone (Rezulin)FDA Link 10/20/2003 - "One study has shown clinical activity of troglitazone treatment in liposarcoma patients" 10/01/2002 - "Thus, this ratio may be an NMR-detectable marker of troglitazone efficacy and response to differentiation therapy for liposarcoma." 03/30/1999 - "We report here the results of three patients with intermediate to high-grade liposarcomas in whom troglitazone administration induced histologic and biochemical differentiation in vivo" 10/01/2002 - "The biochemical changes occurring in the 3T3 F442A cell line and well-differentiated liposarcoma following induction of adipocyte differentiation with the thiazolidinedione troglitazone were measured using high-resolution magic angle spinning (MAS) nuclear magnetic resonance (NMR) spectroscopy" 03/30/1999 - "We have conducted a clinical trial for treatment of patients with advanced liposarcoma by using the peroxisome proliferator-activated receptor-gamma ligand troglitazone, in which extensive correlative laboratory studies of tumor differentiation were performed" Order ALL the reference details at left...
3.	DNA (Deoxyribonucleic Acid)IBA 11/10/1996 - "Cellular DNA content analysis has helped to estimate the biological behavior of a gastrointestinal stromal tumour originating from the stomach and a retroperitoneal dedifferentiated type of a well differentiated liposarcoma" 05/01/2005 - "Only eight of the 17 patients with myxoid/round cell liposarcomas showed changes in DNA copy number (mean 3.4 imbalances)" 01/01/1998 - "Here we describe the use of transfection experiments utilizing DNA from a human pleomorphic liposarcoma to identify a novel gene, designated lip which maps to chromosome 19.Results" 08/16/1994 - "In the case of the liposarcoma, transactivation by the FUS-CHOP protein occurs because the FUS transcriptional activation domain is added to the DNA-binding CHOP protein normally lacking such activity" 09/01/1991 - "In addition, following transfection of DNA from a liposarcoma, we identified an activated gene that failed to hybridize to probes prepared from 10 known human oncogenes (K-ras, H-ras, N-ras, ret, met, trk, mas, dbl, raf and hst) that have previously been detected in DNA transfection experiments" Order ALL the reference details at left...
4.	oil red OIBA 06/01/2008 - "Final diagnosis of a pleomorphic liposarcoma was made by the routine histology and further identified by Oil Red O stain" 03/01/2006 - "Use of Oil Red O stain in the cytologic diagnosis of canine liposarcoma." 03/01/2006 - "OBJECTIVE: The purpose of this study was to prospectively evaluate the value of Oil Red O in identifying lipid to aid in the differentiation of liposarcomas from other types of sarcoma" 03/01/2006 - "CONCLUSION: Our results suggest that Oil Red O staining may be an easy, inexpensive, and useful diagnostic tool for the differentiation of liposarcoma from other mesenchymal neoplasms." 07/01/1982 - "Phosphotungstic acid hematoxylin (PTAH) and oil red O staining of air-dried smears were helpful in differentiating MFH from pleomorphic variants of liposarcoma and rhabdomyosarcoma." Order ALL the reference details at left...
5.	CollagenIBA 02/01/1996 - "Otherwise, in nonlipoma-like liposarcomas, a marked decrease particularly of collagen IV staining was evident" 01/01/1975 - "An intracytoplasmic network of birefringent fibers with the staining reaction of collagen was found in 2 well-differentiated fibrosing liposarcomas..." 08/01/1997 - "Microscopically, these tumors were characterized by areas of ordinary well-differentiated liposarcoma, admixed with discrete nodules comprised of small germinal centers, and separated by an admixture of lymphocytes, spindled stromal cells, collagen, and blood vessels, in which highly atypical tumor cells were embedded" 03/01/1979 - "The well-differentiated, lipoma-like liposarcomas showed cells with a few, large lipid droplets, few organelles and a peripherally located, fairly large nucleus, The well-differentiated liposarcomas of fibrosing type revealed mostly spindle-shaped, fibroblast-like cells, with abundant rough endoplasmic reticulum and inconspicuous lipid inclusions, surrounded by collagen" 12/01/1978 - "Intracellular collagen was detected by electron microscopy in 14 sarcomas including six osteogenic sarcomas, three liposarcomas, three malignant fibrous histiocytomas, one pleomorphic rhabdomyosarcoma, and one childhood rhabdomyosarcoma" Order ALL the reference details at left...
6.	Conditioned Culture MediaIBA 05/01/2000 - "A conditioned medium from a human liposarcoma-derived cell line induces p53-dependent apoptosis in several tumor cell lines." 05/01/2008 - "Frzb transfection of HT1080 (fibrosarcoma) and SW872 (liposarcoma) cell lines and their conditioned media resulted in a significant reduction in cellular invasion, motility, and colony formation in soft agar compared with vector control-transfected cells" Order ALL the reference details at left...
7.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/01/1993 - "This suggests that the use of interferon-alpha and tumor necrosis factor-alpha in combination may be an effective and promising modality for liposarcomas which are refractory to the conventional anticancer treatments." 01/01/1993 - "Complete regression of advanced liposarcoma of the anterior chest wall with interferon-alpha and tumor necrosis factor-alpha." 01/01/1994 - "A limb-saving complete remission of a locally advanced liposarcoma of the left thigh was achieved with isolated regional perfusion of the limb with tumor necrosis factor alpha, interferon gamma and melphalan" Order ALL the reference details at left...
8.	Hematoxylin (Haematoxylon)IBA 03/01/2004 - "Immunostaining using the antibody for Topo-II alpha seems to be useful in recognizing lipoblasts that have been overlooked in hematoxylin-eosin-stained preparations, and is a useful marker for diagnosing liposarcoma." 07/01/1982 - "Phosphotungstic acid hematoxylin (PTAH) and oil red O staining of air-dried smears were helpful in differentiating MFH from pleomorphic variants of liposarcoma and rhabdomyosarcoma." Order ALL the reference details at left...
9.	glucuronyl glucosamine glycan sulfate (Vessel)IBA 07/01/2008 - "RESULTS: A tumoral vessel extending into the renal cortex was seen only in angiomyolipomas (7 and 6 of 9 patients versus 0 and 0 of 11 liposarcomas for readers 1 and 2, respectively; P < 0.005 for both)" 07/01/2008 - "CONCLUSIONS: In the evaluation of a fatty perinephric mass at CT, the presence of a tumoral vessel extending into the renal cortex or a renal parenchymal defect at the site of tumor contact strongly favors the diagnosis of exophytic angiomyolipoma, whereas calcifications suggest liposarcoma." 02/01/2002 - "CONCLUSIONS: This retrospective study suggests that analysis of CT characteristics (linear vascularity, aneurysmal dilatation, bridging vessel sign, hematoma, beak sign and discrete intrarenal fatty tumors) may help to differentiate perinephric angiomyolipoma from perinephric liposarcoma." Order ALL the reference details at left...
10.	Paclitaxel (Taxol)FDA LinkGeneric 03/01/2007 - "Therefore,we consider weekly paclitaxel therapy to be effective for liposarcoma treatment." 03/01/2007 - "We performed weekly paclitaxel therapy for the patient with recurrent liposarcoma" 03/01/2007 - "Weekly paclitaxel therapy is curative for patients with retroperitoneal liposarcoma]" Order ALL the reference details at left...

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 03/15/2008 - "Surgical resection is the mainstay of curative treatment; however, large, high grade liposarcomas may benefit from multimodality treatment with chemotherapy and radiation" 02/18/2008 - "A 70 year-old female presented with a 40 x 40 cm unresectable liposarcoma which showed progression during chemotherapy" 05/01/2007 - "The patient had an antecedent history of a left upper arm liposarcoma treated with surgical resection, chemotherapy, and postoperative radiotherapy 3 years earlier" 09/01/2006 - "A 39-year-old woman underwent placement of a totally implantable venous access device for chemotherapy to treat a recurrent liposarcoma of the left thigh" 05/01/2006 - "A case of liposarcoma of the sigmoid colon mesenterium successfully treated with chemotherapy]" Order ALL the reference details at left...
2.	Combination Drug Therapy (Combination Chemotherapy) 01/01/1982 - "Partial remission (greater than 50%) was obtained in one patient with a liposarcoma who had also responded to prior combination chemotherapy" 06/01/2001 - "He had been diagnosed 13 years before as having a liposarcoma, at which point he was treated with combination chemotherapy, which included anthracycline" 02/01/1999 - "A case of metastatic liposarcoma originating in the retroperitoneum successfully treated with combination chemotherapy]" 01/01/1983 - "This combination chemotherapy is worth trying if a patient has inoperable liposarcoma" 02/01/1999 - "Although the role of chemotherapy for liposarcoma has not been well defined and little data support its use in an adjuvant setting, this combination chemotherapy seemed to be effective for advanced liposarcoma." Order ALL the reference details at left...
3.	Adjuvant Chemotherapy 02/01/1999 - "We reported a 36-year-old woman with metastatic liposarcoma originating in the retroperitoneum, which responded well to adjuvant chemotherapy" 04/01/1993 - "Currently, no evidence exists that adjuvant chemotherapy is indicated for patients with liposarcoma, although numerous studies are being done to investigate its use" 11/01/2006 - "The treatment strategy for mesenteric liposarcoma is, if no distant metastases are detected, surgical resection with a wide surgical margin, often followed by radiation and/or adjuvant chemotherapy for high-risk patients" Order ALL the reference details at left...
4.	Orchiectomy (Orchidectomy) 09/01/1992 - "The present study briefly reviews the literature on spermatic cord liposarcoma and reports an additional case that was treated exclusively by radical orchiectomy" 07/01/2002 - "Local recurrence of liposarcoma of the spermatic cord 6 years after orchiectomy: a case report]" 01/01/1990 - "On the basis of a diagnosis of "malignant mesenchymal neoplasia consistent with liposarcoma," the patient underwent radical orchiectomy" 04/01/2004 - "Radical orchiectomy with wide local excision of the mass is the recommended therapy, while adjuvant radiotherapy may be considered in high-grade tumours and in recurrent liposarcomas" 04/01/2004 - "Preferential treatment of spermatic cord liposarcoma is radical orchiectomy with high ligation of the cord" Order ALL the reference details at left...
5.	Amputation 07/01/1982 - "This study demonstrates that hyperthermic regional perfusion and excision are superior to wide excision or amputation in preventing local recurrence for a liposarcoma of the leg and allow salvage of a functional limb." 01/01/2008 - "Excision biopsy revealed the mass to be a pleomorphic liposarcoma, and below the knee amputation was performed" 11/01/2003 - "RESULTS: In 5 patients (18.5%) the amputation and in 22 cases (81.5%) the limb sparing resection of the liposarcoma was performed" 03/01/1996 - "CASE REPORT: A 56-year-old man with widely metastatic liposarcoma, after left Tower extremity amputation, complained of severe right lower extremity pain" 02/01/1951 - "Liposarcoma of an extremity associated with multiple subcutaneous lipomas; report of two cases treated by amputation." Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Liposarcoma

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 12 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>